INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 411m ago
HOUSE PTR11m ago
SEC 13F11m ago
ROBINHOOD CHAIN11m ago
SEC FORM 4/Open-market purchaseVerified data

Plott Ronald Todd bought PHIO

Director · Phio Pharmaceuticals Corp. · Common Stock, $.0001 par value

Side
BUY
Value
$5,200
Shares
5,000
Price
$1.04
Executed
Sep 29, 2026
Disclosed
Sep 30, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Sep 29 executedSep 30, 2026 disclosed

PHIO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
39/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+5 / 25

    $5K reported value · 13.5% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering+10 / 15

    2 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PHIO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    39
    PT
    Plott Ronald ToddDirector
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$5,150
    5,000 sh
    		Sep 28, 2026Sep 30, 2026
    traded Sep 28, 2026
    		+2dSEC FORM 4

    Evidence

    17
    BJ
    Bitterman Robert JDirector, Chairman, Pres. & CEO
    PHIOPhio Pharmaceuticals Corp.
    Grant or award
    		A—
    400.0K sh
    		Sep 28, 2026Sep 29, 2026
    traded Sep 28, 2026
    		+1dSEC FORM 4

    Evidence

    17
    PT
    Plott Ronald ToddDirector
    PHIOPhio Pharmaceuticals Corp.
    Grant or award
    		A—
    17.0K sh
    		Sep 28, 2026Sep 29, 2026
    traded Sep 28, 2026
    		+1dSEC FORM 4

    Evidence

    21
    CC
    Carson Lisa CabottChief Financial Officer
    PHIOPhio Pharmaceuticals Corp.
    Grant or award
    		A—
    108.0K sh
    		Sep 28, 2026Sep 29, 2026
    traded Sep 28, 2026
    		+1dSEC FORM 4

    Evidence

    43
    BA
    Bradford Patricia ADirector
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$6,583
    6,500 sh
    		Sep 24, 2026Sep 25, 2026
    traded Sep 24, 2026
    		+1dSEC FORM 4

    Evidence

    35
    BJ
    Bitterman Robert JDirector, Chairman, Pres. & CEO
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$2,058
    2,000 sh
    		Sep 22, 2026Sep 23, 2026
    traded Sep 22, 2026
    		+1dSEC FORM 4

    Evidence

    41
    PT
    Plott Ronald ToddDirector
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$17K
    15.0K sh
    		Aug 19, 2026Aug 20, 2026
    traded Aug 19, 2026
    		+1dSEC FORM 4

    Evidence

    25
    BJ
    Bitterman Robert JDirector, Chairman, Pres. & CEO
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$9,900
    10.0K sh
    		Jun 26, 2026Jun 29, 2026
    traded Jun 26, 2026
    		+3dSEC FORM 4

    Evidence

    35
    BJ
    Bitterman Robert JDirector, Chairman, Pres. & CEO
    PHIOPhio Pharmaceuticals Corp.
    Open-market purchase
    		BUY$5,100
    5,000 sh
    		Dec 23, 2025Dec 29, 2025
    traded Dec 23, 2025
    		+6dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001683168-26-007499
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 29, 2026
    Published
    Sep 30, 2026
    Ingested by INSIDER
    Nov 5, 02:14 UTC
    Last re-read
    Nov 5, 02:14 UTC

    Extracted facts

    Filer
    Plott Ronald Todd
    Role
    Director
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    Phio Pharmaceuticals Corp.
    Ticker
    PHIO
    Shares
    5,000
    Price per share
    $1.04
    Value
    $5,200
    Execution date (reported)
    Sep 29, 2026
    Owned after transaction
    42.0K shares
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 5,000
    • Price: $1.04

    = $5,200

    What this establishes

    Plott Ronald Todd filed this Form 4 reporting a open-market purchase of PHIO on Sep 29, 2026. It became public on Sep 30, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Plott Ronald Toddcik:0001768337
    Issuer
    Phio Pharmaceuticals Corp.cik:0001533040

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.